Presenter: Aristo Vojdani, PhD

Original Date: June 10, 2023

According to a very recent article published in The Scientist, 80 million Americans have an autoimmune disease, most of which are lifelong and debilitating. The first revolution in the treatment of autoimmune diseases which began about 50 years ago was the development of blood biomarkers for the screening of these disorders. Presently, in several labs, predicting antibodies have been developed that can guide practitioners not only in finding the underlying causes of autoimmune disorders but in predicting, preventing and treating them as well. The aim of this presentation is to discuss these.

Aristo Vojdani, PhD, MSc, CLS, obtained his MSc and PhD in the fields of microbiology and clinical immunology from Bar-Ilan University in Israel, with postdoctoral studies in comparative immunology at UCLA and tumor immunology at Charles Drew/UCLA School of Medicine and Science. He is presently an adjunct associate professor in the Department of Preventive Medicine at Loma Linda University in California and an adjunct professor at the Lincoln College of Post professional, Graduate, and Continuing Education at the National University of Health Sciences.

His ongoing research focuses on the role of environmental triggers in complex diseases. Dr. Vojdani’s research has resulted in the development of more than 300 antibody assays for the detection of many autoimmune disorders and other diseases. He holds fifteen US patents for laboratory assessments of immune disorders associated with the brain and gut, and has published more than 170 articles in magazines and scientific journals.

1.25 General and 0.25 Pharmacology (Total 1.5 CEUs) approved by OBNM